642 related articles for article (PubMed ID: 31366777)
21. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.
Zieman SJ; Kass DA
Drugs; 2004; 64(5):459-70. PubMed ID: 14977384
[TBL] [Abstract][Full Text] [Related]
22. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
Yamagishi SI; Sotokawauchi A; Matsui T
Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
[TBL] [Abstract][Full Text] [Related]
23. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
Stern DM; Yan SD; Yan SF; Schmidt AM
Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
[TBL] [Abstract][Full Text] [Related]
24. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE-Related Diseases.
Shen CY; Lu CH; Wu CH; Li KJ; Kuo YM; Hsieh SC; Yu CL
Molecules; 2020 Nov; 25(23):. PubMed ID: 33261212
[TBL] [Abstract][Full Text] [Related]
25. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
Bongarzone S; Savickas V; Luzi F; Gee AD
J Med Chem; 2017 Sep; 60(17):7213-7232. PubMed ID: 28482155
[TBL] [Abstract][Full Text] [Related]
27. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
28. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
30. Activation of RAGE-dependent endoplasmic reticulum stress associates with exacerbated postmyocardial infarction ventricular arrhythmias in diabetes.
Liu Z; Zhang Y; Pan S; Qiu C; Jia H; Wang Y; Zhu H
Am J Physiol Endocrinol Metab; 2021 Mar; 320(3):E539-E550. PubMed ID: 33459180
[TBL] [Abstract][Full Text] [Related]
31. Fructose causes endothelial cell damage via activation of advanced glycation end products-receptor system.
Sotokawauchi A; Matsui T; Higashimoto Y; Yamagishi SI
Diab Vasc Dis Res; 2019 Nov; 16(6):556-561. PubMed ID: 31375034
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review.
Jud P; Sourij H
Diabetes Res Clin Pract; 2019 Feb; 148():54-63. PubMed ID: 30500546
[TBL] [Abstract][Full Text] [Related]
33. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
34. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Khalid M; Petroianu G; Adem A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
[TBL] [Abstract][Full Text] [Related]
35. Protective role of sulphoraphane against vascular complications in diabetes.
Yamagishi S; Matsui T
Pharm Biol; 2016 Oct; 54(10):2329-39. PubMed ID: 26841240
[TBL] [Abstract][Full Text] [Related]
36. All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.
Oczypok EA; Perkins TN; Oury TD
Paediatr Respir Rev; 2017 Jun; 23():40-49. PubMed ID: 28416135
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
38. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
[TBL] [Abstract][Full Text] [Related]
39. Advanced glycation endproducts in diabetes and diabetic complications.
Vlassara H; Striker GE
Endocrinol Metab Clin North Am; 2013 Dec; 42(4):697-719. PubMed ID: 24286947
[TBL] [Abstract][Full Text] [Related]
40. The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes.
Snelson M; Lucut E; Coughlan MT
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
